Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Nimenrix in Healthy Infants (3 and 12 Months)
NCT04819113Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen in meningococcal disease, sponsored by Pfizer. Started Apr 2021; status: completed.
02
Drugs
Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT04819113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819113.